Karlijn Verkerk - Netherlands Cancer Institute, Oncode Institute

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

The Pathway Alteration Load As a Pan-Cancer Determinant of Outcome of Targeted Therapies: Results from the Drug Rediscovery Protocol (DRUP)

Karlijn Verkerk,Laurien Joanna Zeverijn,Joris van de Haar,Paul Roepman,Birgit Geurts, Ilse Anna Catharina Spiekman,Vincent van der Noort,Jade Maxime van Berge Henegouwen,Louisa Rose Hoes,Hanneke van der Wijngaart,Anne M. L. Jansen,Wendy W. J. de Leng, Henk M. W. Verheul,Hans Gelderblom,Emile E. Voest

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

130P Ipilimumab Plus Nivolumab (ipi+nivo) in Patients with Tumors Harboring High Tumor Mutational Burden or Load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP)

S.F. Haj Mohammad,K. Verkerk,L.J. Zeverijn,B.S. Geurts, I.A.C. Spiekman, F. Verbeek,P. Roepman, A. Jansen,W. de Leng,D. Robbrecht, S. Marchetti,H.M.W. Verheul, E.E. Voest, H. Gelderblom

Annals of Oncology (2024)

引用0浏览0引用

1550P Addressing Uncertainties of Clinical Value and Improving Access for Newly Authorised Indications Through DRUG-Access Protocol (Dap)-Like Platforms: Joint Collection and Evaluation of Real-World Evidence

S.B. van Waalwijk van Doorn-Khosrovani, A.H. Huisman, H.J.L. Timmer,K. Verkerk, F. Verbeek,L. Fagereng, A. Helland,B. Ryll, K. Tasken, K. Jalkanen, J. Oliveira,U.N. Lassen, J-Y. Blay, H. Gelderblom,A. Reyners,F.A. Eskens, E.F. Smit, E.E. Voest, H. Bloemendal

Annals of Oncology (2024)

引用0浏览0引用

The Evolution of Precision Oncology: the Ongoing Impact of the Drug Rediscovery Protocol (DRUP)